ArticleTargeted oncology2025

Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study.

Hiroshi Doi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.